Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases

Detalhes bibliográficos
Autor(a) principal: Oliveira, Isabel Matos
Data de Publicação: 2021
Outros Autores: Fernandes, Diogo Castro, Maia, F. Raquel, Canadas, Raphael Faustino, Reis, R. L., Oliveira, J. M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/1822/73752
Resumo: Rheumatoid Arthritis (RA) is an incurable autoimmune disease that promotes the chronic impairment of patientsâ mobility. For this reason, it is vital to develop therapies that target early inflammatory symptoms and act before permanent articular damage. The present study offers two novel therapies based in advanced drug delivery systems for RA treatment: encapsulated chondroitin sulfate modified poly(amidoamine) dendrimer nanoparticles (NPs) covalently bonded to monoclonal anti-TNF α antibody in both Tyramine-Gellan Gum and Tyramine-Gellan Gum/Silk Fibroin hydrogels. Using pro-inflammatory THP-1 (i.e., human monocytic cell line), the therapy was tested in an inflammation in vitro model under both static and dynamic conditions. Firstly, we demonstrated effective NP-antibody functionalization and TNF-α capture. Upon encapsulation, the NPs were released steadily over 21 days. Moreover, in static conditions, the approaches presented good anti-inflammatory activity over time, enabling the retainment of a high percentage of TNF α. To mimic the physiological conditions of the human body, the hydrogels were evaluated in a dual-chamber bioreactor. Dynamic in vitro studies showed absent cytotoxicity in THP-1 cells and a significant reduction of TNF-α in suspension over 14 days for both hydrogels. Thus, the developed approach showed potential for use as personalized medicine to obtain better therapeutic outcomes and decreased adverse effects.
id RCAP_408f1790024712d40dc67dbe50c633a8
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/73752
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str
spelling Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseasesBioreactorDendrimersDynamic conditionsNanocomposite hydrogelsStatic conditionsTherapeutic efficacyScience & TechnologyRheumatoid Arthritis (RA) is an incurable autoimmune disease that promotes the chronic impairment of patientsâ mobility. For this reason, it is vital to develop therapies that target early inflammatory symptoms and act before permanent articular damage. The present study offers two novel therapies based in advanced drug delivery systems for RA treatment: encapsulated chondroitin sulfate modified poly(amidoamine) dendrimer nanoparticles (NPs) covalently bonded to monoclonal anti-TNF α antibody in both Tyramine-Gellan Gum and Tyramine-Gellan Gum/Silk Fibroin hydrogels. Using pro-inflammatory THP-1 (i.e., human monocytic cell line), the therapy was tested in an inflammation in vitro model under both static and dynamic conditions. Firstly, we demonstrated effective NP-antibody functionalization and TNF-α capture. Upon encapsulation, the NPs were released steadily over 21 days. Moreover, in static conditions, the approaches presented good anti-inflammatory activity over time, enabling the retainment of a high percentage of TNF α. To mimic the physiological conditions of the human body, the hydrogels were evaluated in a dual-chamber bioreactor. Dynamic in vitro studies showed absent cytotoxicity in THP-1 cells and a significant reduction of TNF-α in suspension over 14 days for both hydrogels. Thus, the developed approach showed potential for use as personalized medicine to obtain better therapeutic outcomes and decreased adverse effects.The authors thank the financial support provided under the Norte2020 project (NORTE-08-5369-FSE000044). D.C.F. acknowledges the Portuguese Foundation for Science and Technology (FCT) for her PhD scholarship (PD/BD/143081/2018) and F.R.M. for her contract under the Transitional Rule DL 57/2016 (CTTI-57/18-I3BS(5)). The FCT distinction attributed to J.M.O. under the Investigator FCT program (number IF/01285/2015) is also greatly acknowledged.MDPIUniversidade do MinhoOliveira, Isabel MatosFernandes, Diogo CastroMaia, F. RaquelCanadas, Raphael FaustinoReis, R. L.Oliveira, J. M.2021-072021-07-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/73752engOliveira I. M., Fernandes D. C., Maia F. R., Canadas R. F., Reis R. L., Dr. Oliveira J. M. Bioengineered Nanoparticles Loaded-Hydrogels to Target TNF Alpha in Inflammatory Diseases, Pharmaceutics, Vol. 13, Issue 8, pp. 1-14, doi:10.3390/pharmaceutics13081111, 20211999-492310.3390/pharmaceutics13081111https://www.mdpi.com/1999-4923/13/8/1111info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:02:39ZPortal AgregadorONG
dc.title.none.fl_str_mv Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases
title Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases
spellingShingle Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases
Oliveira, Isabel Matos
Bioreactor
Dendrimers
Dynamic conditions
Nanocomposite hydrogels
Static conditions
Therapeutic efficacy
Science & Technology
title_short Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases
title_full Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases
title_fullStr Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases
title_full_unstemmed Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases
title_sort Bioengineered nanoparticles loaded-hydrogels to target TNF Alpha in inflammatory diseases
author Oliveira, Isabel Matos
author_facet Oliveira, Isabel Matos
Fernandes, Diogo Castro
Maia, F. Raquel
Canadas, Raphael Faustino
Reis, R. L.
Oliveira, J. M.
author_role author
author2 Fernandes, Diogo Castro
Maia, F. Raquel
Canadas, Raphael Faustino
Reis, R. L.
Oliveira, J. M.
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Oliveira, Isabel Matos
Fernandes, Diogo Castro
Maia, F. Raquel
Canadas, Raphael Faustino
Reis, R. L.
Oliveira, J. M.
dc.subject.por.fl_str_mv Bioreactor
Dendrimers
Dynamic conditions
Nanocomposite hydrogels
Static conditions
Therapeutic efficacy
Science & Technology
topic Bioreactor
Dendrimers
Dynamic conditions
Nanocomposite hydrogels
Static conditions
Therapeutic efficacy
Science & Technology
description Rheumatoid Arthritis (RA) is an incurable autoimmune disease that promotes the chronic impairment of patientsâ mobility. For this reason, it is vital to develop therapies that target early inflammatory symptoms and act before permanent articular damage. The present study offers two novel therapies based in advanced drug delivery systems for RA treatment: encapsulated chondroitin sulfate modified poly(amidoamine) dendrimer nanoparticles (NPs) covalently bonded to monoclonal anti-TNF α antibody in both Tyramine-Gellan Gum and Tyramine-Gellan Gum/Silk Fibroin hydrogels. Using pro-inflammatory THP-1 (i.e., human monocytic cell line), the therapy was tested in an inflammation in vitro model under both static and dynamic conditions. Firstly, we demonstrated effective NP-antibody functionalization and TNF-α capture. Upon encapsulation, the NPs were released steadily over 21 days. Moreover, in static conditions, the approaches presented good anti-inflammatory activity over time, enabling the retainment of a high percentage of TNF α. To mimic the physiological conditions of the human body, the hydrogels were evaluated in a dual-chamber bioreactor. Dynamic in vitro studies showed absent cytotoxicity in THP-1 cells and a significant reduction of TNF-α in suspension over 14 days for both hydrogels. Thus, the developed approach showed potential for use as personalized medicine to obtain better therapeutic outcomes and decreased adverse effects.
publishDate 2021
dc.date.none.fl_str_mv 2021-07
2021-07-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/73752
url http://hdl.handle.net/1822/73752
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Oliveira I. M., Fernandes D. C., Maia F. R., Canadas R. F., Reis R. L., Dr. Oliveira J. M. Bioengineered Nanoparticles Loaded-Hydrogels to Target TNF Alpha in Inflammatory Diseases, Pharmaceutics, Vol. 13, Issue 8, pp. 1-14, doi:10.3390/pharmaceutics13081111, 2021
1999-4923
10.3390/pharmaceutics13081111
https://www.mdpi.com/1999-4923/13/8/1111
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1777303669363965952

Registros relacionados